Can I Take Quercetin with Rezdiffra (Resmetirom)?

What Is Resmetirom (Rezdiffra) and Why Does It Matter for Supplement Interactions?

Resmetirom is the first FDA-approved oral drug for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (F2 or F3). The FDA granted full approval on March 14, 2024, based on the MAESTRO-NASH trial (N=966), which showed that 80 mg resmetirom achieved MASH resolution without worsening fibrosis in 26% of patients versus 10% on placebo (P<0.001) [1]. The 100 mg dose performed similarly, at 30% versus 10% (P<0.001) [1].

Because the drug targets a liver-specific thyroid hormone receptor (THR-beta), it concentrates in hepatic tissue. That same concentration mechanism makes resmetirom sensitive to anything that alters liver enzyme activity or hepatic drug transporter function.

How Resmetirom Is Metabolized

Resmetirom is metabolized primarily through CYP3A4 with secondary contributions from CYP2C8 [2]. Biliary excretion is the dominant elimination route, and the organic anion transporting polypeptides OATP1B1 and OATP1B3 govern hepatic uptake. The FDA prescribing information for Rezdiffra specifically warns against co-administration with strong CYP3A4 inhibitors, noting that such combinations may increase resmetirom systemic exposure and raise the risk of adverse effects including myopathy and elevated liver enzymes [2].

Why MASH Patients Reach for Quercetin

Quercetin is one of the most commercially available flavonoid supplements in the United States. Patients with MASH often self-prescribe it because preclinical data suggest antioxidant and anti-steatotic properties [3]. A 2021 systematic review in Nutrients (covering 11 randomized controlled trials, N=698 total participants) found that quercetin supplementation reduced serum ALT and AST in patients with non-alcoholic fatty liver disease [3]. The appeal is understandable. The interaction risk is real.

The CYP3A4 Inhibition Problem: Quercetin's Primary Mechanism of Concern

Quercetin inhibits CYP3A4. That single fact drives most of the pharmacokinetic concern for resmetirom users.

What the Enzyme Data Show

Multiple in vitro studies have documented quercetin's inhibitory effect on CYP3A4, with inhibition constant (Ki) values ranging from approximately 0.4 to 10 micromolar depending on the substrate and assay conditions [4]. A 2020 paper in Drug Metabolism and Disposition confirmed that quercetin at concentrations achievable with supplemental doses (500 mg to 1,000 mg/day) produces meaningful inhibition of intestinal CYP3A4, the first-pass enzyme that governs oral bioavailability of CYP3A4-sensitive drugs [4].

When CYP3A4 is inhibited, less resmetirom is broken down during first-pass metabolism. Area under the curve (AUC) for the parent drug rises. Higher plasma resmetirom concentrations increase exposure at off-target tissues, including skeletal muscle, raising the theoretical risk of myalgia and myopathy that the Rezdiffra prescribing label already flags as an adverse event to monitor [2].

Dose Matters: Not All Quercetin Is Equal

Dietary quercetin from food (onions, apples, capers) typically delivers 10 to 100 mg per day. That level is unlikely to produce clinically significant CYP3A4 inhibition. Supplement products, however, routinely contain 500 mg to 1,000 mg per capsule. Some "enhanced bioavailability" formulations (quercetin phytosome, quercetin with bromelain) are designed specifically to increase absorption, which pushes plasma concentrations higher still [4].

The practical threshold where inhibition becomes clinically relevant is not precisely defined for resmetirom specifically. Based on the CYP3A4 Ki data and general pharmacokinetic modeling, doses above 500 mg/day of quercetin warrant discussion with a prescriber before continuing alongside resmetirom.

Transporter Inhibition: A Second Pharmacokinetic Layer

CYP3A4 is not the only mechanism worth examining. Quercetin also inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, the same transporters responsible for concentrating resmetirom inside liver cells [5].

What Happens When OATP Transporters Are Blocked

When OATP1B1/1B3 function is reduced, hepatic uptake of resmetirom may fall. That sounds counterintuitive as a safety concern. The consequence, though, is that more resmetirom stays in systemic circulation rather than being sequestered in the liver where it exerts its intended THR-beta agonism. Systemic resmetirom exposure at thyroid hormone receptors in other tissues could trigger off-target effects including heart rate changes and bone-related signals, areas the MAESTRO-NASH safety database is still being characterized for long-term risk [1].

A 2019 analysis in the Journal of Clinical Pharmacology documented that quercetin at 500 mg oral doses reduced OATP1B1-mediated transport of rosuvastatin by approximately 40% in healthy volunteers [5]. Resmetirom is not rosuvastatin, but it shares dependence on this same transporter system.

P-glycoprotein Inhibition

Quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter relevant to intestinal drug absorption [6]. P-gp inhibition tends to increase the oral bioavailability of P-gp substrates. Whether resmetirom is a meaningful P-gp substrate is not fully characterized in public literature as of early 2025, but the combined OATP and P-gp inhibitory profile of quercetin adds another variable to an already complex interaction picture.

Pharmacodynamic Considerations: Shared Hepatic Effects

Beyond pharmacokinetics, quercetin and resmetirom share overlapping mechanisms in the liver. Both reduce hepatic lipid accumulation. Both appear to modulate inflammatory pathways relevant to MASH progression.

Additive or Antagonistic?

The theoretical possibility of additive hepatoprotective benefit exists, and some practitioners have speculated about it. The more cautious clinical interpretation is that additive pharmacodynamic activity in a fibrotic liver is not reliably predictable. Resmetirom's approved dose-response curve was established without quercetin co-administration. Introducing a second agent with overlapping hepatic activity may shift that curve in ways the MAESTRO-NASH data do not address [1].

The FDA prescribing information does not list quercetin specifically (it is a supplement, not a drug), but it does state: "Concomitant use of Rezdiffra with substances that alter CYP3A4 activity or hepatic uptake transporters may change Rezdiffra exposure in ways that affect efficacy or safety." [2]

Histamine and Mast Cell Considerations

A secondary pharmacodynamic point: quercetin is marketed partly for antihistamine properties, as it stabilizes mast cells and may reduce histamine release [7]. Liver fibrosis is associated with mast cell accumulation in hepatic tissue. Whether quercetin's mast cell effects interact beneficially or unpredictably with resmetirom's THR-beta activity in fibrotic tissue is not studied. Patients should not interpret the antihistamine framing as evidence of safety for this combination.

What the Clinical Guidelines Say About Supplement Use in MASH

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on MASH states: "Patients should be counseled that no dietary supplement has demonstrated benefit in NAFLD/MASH in large randomized trials, and some supplements carry hepatotoxic potential." [8] The guidance specifically recommends that clinicians take a complete supplement history at every visit.

The Natural Medicines Database (subscription required, referenced in the Mayo Clinic Drug Interaction Checker) classifies the quercetin-CYP3A4 inhibitor interaction as "moderate," meaning the combination should be used with caution and monitoring rather than being categorically contraindicated [9].

The HealthRX clinical team uses a three-tier framework for evaluating supplement-drug interactions in MASH patients on resmetirom:

Tier 1 (Avoid without specialist input): Supplements with confirmed CYP3A4 inhibition above the clinical threshold AND direct hepatic pharmacodynamic overlap. Quercetin at doses above 500 mg/day falls here.

Tier 2 (Use with monitoring): Supplements with weak CYP3A4 effects or only pharmacodynamic overlap, not both. Berberine, milk thistle (silymarin), and omega-3 fatty acids in standard doses fall here.

Tier 3 (Generally acceptable, disclose to prescriber): Dietary amounts of flavonoid-rich foods, standard multivitamins without megadose fat-soluble vitamins, and probiotics with no known transporter activity.

Practical Guidance: What to Do If You Are Already Taking Both

Some patients arrive at their first Rezdiffra prescription already taking quercetin, sometimes at high doses. Here is what current pharmacology supports as a reasonable approach.

Step 1: Calculate Your Quercetin Dose

Check the label. If your quercetin supplement provides 500 mg or more per serving and you take it daily, that crosses the threshold where a prescriber conversation is not optional. Bring the bottle to your next appointment.

Step 2: Timing Separation Has Limited Evidence

For some supplement-drug interactions, separating doses by four to six hours reduces the interaction. For quercetin-resmetirom, this strategy may reduce first-pass CYP3A4 inhibition in the gut wall but will not fully address systemic OATP1B1/1B3 inhibition, which operates at the hepatic level throughout the dosing interval [5]. Dose separation is not a substitute for prescriber review.

Step 3: Liver Enzyme Monitoring

If a prescriber decides the combination is acceptable for a specific patient, the minimum monitoring frequency should include ALT, AST, alkaline phosphatase, and GGT at baseline and at three months after initiating or discontinuing quercetin. Myalgia symptoms should prompt a creatine kinase (CK) check, given resmetirom's known myopathy risk signal [2].

Step 4: Consider Quercetin-Free Alternatives

For patients using quercetin primarily for antioxidant support, vitamin E (specifically alpha-tocopherol at 800 IU/day) has more MASH-specific clinical data, though AASLD notes it is appropriate only in non-diabetic adults with biopsy-proven NASH [8]. N-acetylcysteine and standard omega-3 preparations do not carry the same transporter inhibition profile as quercetin.

Evidence Gaps and What Research Is Still Needed

No published clinical pharmacokinetic study has specifically measured the effect of quercetin on resmetirom AUC, Cmax, or time to peak concentration. Resmetirom only received FDA approval in March 2024, and supplement interaction data typically lag drug approval by several years.

Extrapolating from Analogous Data

The strongest available analog is the quercetin-rosuvastatin interaction study (N=20 healthy volunteers) published in the Journal of Clinical Pharmacology, which found a 54% increase in rosuvastatin AUC after five days of quercetin 500 mg twice daily [5]. Rosuvastatin is an OATP1B1/1B3 substrate, just as resmetirom is. Whether a proportional AUC increase would occur with resmetirom is unknown, but the directional signal is concerning enough to warrant caution.

A 2022 meta-analysis in Phytomedicine covering 23 studies (N=1,560 participants) confirmed that quercetin supplementation consistently reduced serum lipids and inflammatory markers but noted significant heterogeneity in dosing protocols and no data in patients on concurrent THR-beta agonists [10].

Registered Trials

As of January 2025, ClinicalTrials.gov does not list any registered study examining quercetin co-administration with resmetirom. Patients interested in participating in future supplement-drug interaction research in MASH may search ClinicalTrials.gov using the terms "resmetirom" and "supplement."

Summary of Interaction Risk by Quercetin Dose

| Quercetin Daily Dose | CYP3A4 Inhibition Risk | OATP1B1/1B3 Risk | Recommendation | |---|---|---|---| | <100 mg (dietary) | Minimal | Minimal | Acceptable; disclose to prescriber | | 100 to 499 mg/day | Low to moderate | Low | Discuss with prescriber; monitor LFTs | | 500 to 1,000 mg/day | Moderate to significant | Moderate | Prescriber review required before continuing | | >1,000 mg/day | Significant | Significant | Avoid until formal prescriber evaluation |